• 1
    La Montagna G, Baruffo A, Abbadessa S, Maja L, Tirri R. Evidence for bone resorption in systemic sclerosis. J Rheumatol 1995; 22: 7979.
  • 2
    Loucks J, Pope JE. Osteoporosis in scleroderma. Semin Arthritis Rheum 2005; 34: 67882.
  • 3
    Yuen SY, Rochwerg B, Ouimet J, Pope JE. Patients with scleroderma may have increased risk of osteoporosis: a comparison to rheumatoid arthritis and noninflammatory musculoskeletal conditions. J Rheumatol 2008; 35: 10738.
  • 4
    Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int 2012; 23: 5817.
  • 5
    Broy SB, Tanner SB. Official positions for FRAX clinical regarding rheumatoid arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. J Clin Densitom 2011; 14: 1849.
  • 6
    Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 310412.
  • 7
    Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993; 306: 558.
  • 8
    Allanore Y, Avouac J, Wipff J, Kahan A. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007; 8: 60715.
  • 9
    La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis: evidence of a participating role of earlier menopause. Clin Rheumatol 1991; 10: 1822.
  • 10
    Frediani B, Baldi F, Falsetti P, Acciai C, Filippou G, Spreafico A, et al. Bone mineral density in patients with systemic sclerosis [letter]. Ann Rheum Dis 2004; 63: 3267.
  • 11
    Souza RB, Borges CT, Takayama L, Aldrighi JM, Pereira RM. Systemic sclerosis and bone loss: the role of the disease and body composition. Scand J Rheumatol 2006; 35: 3847.
  • 12
    Sampaio-Barros PD, Costa-Paiva L, Filardi S, Sachetto Z, Samara AM, Marques-Neto JF. Prognostic factors of low bone mineral density in systemic sclerosis. Clin Exp Rheumatol 2005; 23: 1804.
  • 13
    Frediani B, Baldi F, Falsetti P, Acciai C, Filippou G, Spreafico A, et al. Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin Exp Rheumatol 2004; 22: 3138.
  • 14
    Neumann K, Wallace DJ, Metzger AL. Osteoporosis: less than expected in patients with scleroderma? [Letter]. J Rheumatol 2000; 27: 18223.
  • 15
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 16
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 17
    Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003; 21 Suppl: S3941.
  • 18
    Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 Suppl: S426.
  • 19
    Hollis BW, Wagner CL. Normal serum vitamin D levels [letter]. N Engl J Med 2005; 352: 5156.
  • 20
    Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 26681.
  • 21
    Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009; 36: 19249.
  • 22
    Avouac J, Meune C, Ruiz B, Couraud PO, Uzan G, Boileau C, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis 2012; 71: 3949.
  • 23
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 281622.
  • 24
    Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. Ann Rheum Dis 2010; 69: 21821.
  • 25
    Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009; 11: R30.
  • 26
    Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 2010; 21: 128793.
  • 27
    Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Proximal femur bone mineral levels of US adults. Osteoporos Int 1995; 5: 389409.
  • 28
    Orwoll ES, Bauer DC, Vogt TM, Fox KM, for the Study of Osteoporotic Fractures Research Group. Axial bone mass in older women. Ann Intern Med 1996; 124: 18796.
  • 29
    Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI, et al. Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric x-ray absorptiometry. Osteoporos Int 2005; 16: 3542.
  • 30
    Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP, Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009; 68: 183942.
  • 31
    Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 237.
  • 32
    Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009; 68: 3736.
  • 33
    Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166: 2495501.
  • 34
    Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008; 149: 24250.
  • 35
    Caramaschi P, Dalla Gassa A, Ruzzenente O, Volpe A, Ravagnani V, Tinazzi I, et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2011; 29: 141925.
  • 36
    Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol 2011; 38: 539.
  • 37
    Rios Fernandez R, Fernandez Roldan C, Callejas Rubio JL, Ortego Centeno N. Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain [letter]. J Rheumatol 2010; 37: 13556.
  • 38
    Belloli L, Ughi N, Marasini B. Vitamin D in systemic sclerosis [letter]. Clin Rheumatol 2011; 30: 1456.
  • 39
    Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone micro-architecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 2011; 26: 27629.